Polybromo 1 (PBRM1) inactivating mutations are associated with clinical benefit from immune checkpoint inhibitor treatments in clear cell renal cell carcinoma (ccRCC). This evidence concerns the gene PBRM1 and nonpapillary renal cell carcinoma.